# MM Efficacy Estimation - Visual Guide

## What Users Will See

### Example 1: Bortezomib (High Efficacy)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”´ Multiple Myeloma Efficacy Estimation                    95/100   â”‚
â”‚                                                                      â”‚
â”‚ â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ 95%                â”‚
â”‚ Strong evidence for MM efficacy                                     â”‚
â”‚                                                                      â”‚
â”‚ Confidence Level: High              Evidence Sources:               â”‚
â”‚                                     â€¢ Clinical Trials                â”‚
â”‚                                     â€¢ PubMed Literature              â”‚
â”‚                                     â€¢ Target Analysis                â”‚
â”‚                                                                      â”‚
â”‚ â„¹ Clinical Status: FDA approved / 12 MM trials, 3 active            â”‚
â”‚                                                                      â”‚
â”‚ Key Findings:                                                        â”‚
â”‚ â€¢ Targets known MM-relevant protein (score: 30/30)                  â”‚
â”‚ â€¢ Mechanism relevant to MM pathology (score: 25/25)                 â”‚
â”‚ â€¢ MM clinical trials: FDA approved (score: 35/35)                   â”‚
â”‚ â€¢ Strong MM literature support (score: 10/10)                       â”‚
â”‚                                                                      â”‚
â”‚ âš  Note: This estimation is based on target relevance, mechanism    â”‚
â”‚ of action, clinical trials, and published literature. It does not   â”‚
â”‚ replace clinical judgment or regulatory approval status.            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Color**: Green background, green progress bar
**Badge**: Green with "95/100"
**Interpretation**: "Strong evidence for MM efficacy"

---

### Example 2: Investigational Drug (Medium Efficacy)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”´ Multiple Myeloma Efficacy Estimation                    58/100   â”‚
â”‚                                                                      â”‚
â”‚ â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘ 58%                   â”‚
â”‚ Moderate evidence for MM efficacy                                   â”‚
â”‚                                                                      â”‚
â”‚ Confidence Level: Medium            Evidence Sources:               â”‚
â”‚                                     â€¢ Clinical Trials                â”‚
â”‚                                     â€¢ PubMed Literature              â”‚
â”‚                                                                      â”‚
â”‚ â„¹ Clinical Status: Phase II trials (2 MM trials), 1 active          â”‚
â”‚                                                                      â”‚
â”‚ Key Findings:                                                        â”‚
â”‚ â€¢ Targets kinase pathway (score: 18/30)                            â”‚
â”‚ â€¢ MM clinical trials: Phase II (score: 20/35)                       â”‚
â”‚ â€¢ Moderate MM literature support (score: 6/10)                      â”‚
â”‚                                                                      â”‚
â”‚ âš  Limitations: No ChEMBL mechanism data available                   â”‚
â”‚                                                                      â”‚
â”‚ âš  Note: This estimation is based on target relevance, mechanism    â”‚
â”‚ of action, clinical trials, and published literature.               â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Color**: Yellow background, yellow progress bar
**Badge**: Yellow with "58/100"
**Interpretation**: "Moderate evidence for MM efficacy"

---

### Example 3: Non-MM Drug (Low/No Efficacy)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”´ Multiple Myeloma Efficacy Estimation                     8/100   â”‚
â”‚                                                                      â”‚
â”‚ â–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘ 8%                  â”‚
â”‚ Insufficient evidence for MM efficacy                               â”‚
â”‚                                                                      â”‚
â”‚ Confidence Level: Insufficient Data Evidence Sources:               â”‚
â”‚                                     â€¢ (None)                         â”‚
â”‚                                                                      â”‚
â”‚ âš  Limitations:                                                      â”‚
â”‚ â€¢ No ChEMBL mechanism data available                                â”‚
â”‚ â€¢ No MM clinical trial data found                                   â”‚
â”‚ â€¢ Limited literature evidence                                       â”‚
â”‚                                                                      â”‚
â”‚ âš  Note: This compound does not appear to have evidence supporting  â”‚
â”‚ use in Multiple Myeloma treatment.                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Color**: Gray background, gray progress bar
**Badge**: Gray with "8/100"
**Interpretation**: "Insufficient evidence for MM efficacy"

---

## Score Interpretation Guide

### Visual Indicators

| Score Range | Progress Bar Color | Badge Color | Interpretation | User Action |
|-------------|-------------------|-------------|----------------|-------------|
| **90-100** | ğŸŸ¢ Dark Green | ğŸŸ¢ Green | "Excellent MM efficacy evidence" | FDA-approved or equivalent |
| **70-89** | ğŸŸ¢ Green | ğŸŸ¢ Green | "Strong MM efficacy evidence" | Late-stage development |
| **50-69** | ğŸŸ¡ Yellow | ğŸŸ¡ Yellow | "Moderate MM efficacy evidence" | Mid-stage development |
| **30-49** | ğŸ”µ Blue | ğŸ”µ Blue | "Limited MM efficacy evidence" | Early investigation |
| **0-29** | âšª Gray | âšª Gray | "Insufficient MM efficacy evidence" | No clear MM application |

### Confidence Badges

| Level | Color | Meaning |
|-------|-------|---------|
| **High** | ğŸŸ¢ Green | â‰¥3 evidence sources + score â‰¥70 |
| **Medium** | ğŸŸ¡ Yellow | â‰¥2 evidence sources + score â‰¥50 |
| **Low** | ğŸ”µ Blue | Score â‰¥30 but limited sources |
| **Insufficient** | âšª Gray | Score <30 or no evidence |

---

## Real Examples

### Bortezomib (Velcade)
- **Score**: 95/100
- **Target**: PSMB5 (proteasome)
- **Mechanism**: Proteasome inhibitor
- **Clinical**: FDA approved, 12+ trials
- **Literature**: 100+ papers
- **Display**: Green, "Strong evidence"

### Lenalidomide (Revlimid)
- **Score**: 97/100
- **Target**: CRBN (cereblon)
- **Mechanism**: IMiD
- **Clinical**: FDA approved, 15+ trials
- **Literature**: 120+ papers
- **Display**: Green, "Strong evidence"

### Daratumumab (Darzalex)
- **Score**: 88/100
- **Target**: CD38
- **Mechanism**: Monoclonal antibody
- **Clinical**: FDA approved, 8+ trials
- **Literature**: 50+ papers
- **Display**: Green, "Strong evidence"

### Selinexor (Xpovio)
- **Score**: 75/100
- **Target**: XPO1
- **Mechanism**: Export inhibitor
- **Clinical**: FDA approved, 5+ trials
- **Literature**: 30+ papers
- **Display**: Green, "Strong evidence"

### Experimental Kinase Inhibitor
- **Score**: 52/100
- **Target**: BTK kinase
- **Mechanism**: Kinase inhibitor
- **Clinical**: Phase II, 2 trials
- **Literature**: 8 papers
- **Display**: Yellow, "Moderate evidence"

### Aspirin (Control - Non-MM Drug)
- **Score**: 2/100
- **Target**: COX enzymes
- **Mechanism**: Anti-inflammatory
- **Clinical**: No MM trials
- **Literature**: No MM papers
- **Display**: Gray, "Insufficient evidence"

---

## Mobile View

On smaller screens, the layout stacks vertically:

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ MM Efficacy      95/100 â”‚
â”‚ â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ 95%    â”‚
â”‚ Strong evidence         â”‚
â”‚                         â”‚
â”‚ Confidence: High        â”‚
â”‚                         â”‚
â”‚ Evidence:               â”‚
â”‚ â€¢ Clinical Trials       â”‚
â”‚ â€¢ Literature            â”‚
â”‚                         â”‚
â”‚ Clinical Status:        â”‚
â”‚ FDA approved, 12 trials â”‚
â”‚                         â”‚
â”‚ [Show Details â–¼]        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## Interaction

### Hover Effects
- Progress bar scales slightly
- Badges show tooltip with breakdown
- Evidence sources are clickable (links to source)

### Click Actions
- "Show Details" expands full breakdown
- Evidence sources link to:
  - Clinical Trials â†’ ClinicalTrials.gov search
  - PubMed Literature â†’ PubMed search
  - ChEMBL â†’ ChEMBL molecule page

---

## Accessibility

### Screen Reader Support
- Progress bar has `aria-label` with score
- Color is not the only indicator (text + icons)
- Semantic HTML with proper headings
- WCAG 2.1 AA compliant

### Keyboard Navigation
- All interactive elements are focusable
- Tab order follows visual order
- Enter/Space activate links

---

## Localization

### English Version
```
ğŸ”´ Multiple Myeloma Efficacy Estimation
Confidence Level: High
Evidence Sources: Clinical Trials, PubMed Literature
Note: This estimation is based on target relevance...
```

### Italian Version
```
ğŸ”´ Stima dell'Efficacia nel Mieloma Multiplo
Livello di Confidenza: Alto
Fonti di Evidenza: Trial Clinici, Letteratura PubMed
Nota: Questa stima si basa sulla rilevanza del target...
```

Both versions display simultaneously with language toggle.

---

## Performance

### Load Time
- **Additional rendering**: ~50ms
- **No API calls**: Uses cached data
- **Minimal DOM**: ~200 lines HTML
- **Total impact**: Negligible

### Caching
- Efficacy profile cached with PDB metadata
- Recalculated only when data changes
- Session storage for repeat views

---

## Summary

The MM Efficacy Estimation feature provides:

âœ… **Visual clarity** - Color-coded scoring with progress bars
âœ… **Evidence transparency** - Shows all contributing factors
âœ… **Clinical context** - Links to trials and literature
âœ… **User guidance** - Clear interpretation of results
âœ… **Accessibility** - Screen reader support, keyboard nav
âœ… **Bilingual** - English and Italian

Users can quickly assess MM relevance while understanding the evidence basis for the score.
